Baby food is no infantile business. It's a huge growth opportunity, but a few key leaders have struggled recently. French nutrition leader Danone (NASDAQOTH:DANOY) has suffered from the fallout of a recall in Asia. And while Swiss nutrition giant Nestle (NASDAQOTH:NSRGY) avoided a fine in China's baby food price-fixing probe, the company's still battling a tough European market to grow sales.
Through the struggle, diversified medical giant Abbott Labs (NYSE:ABT) continues to shine. While Abbott didn't escape China's probe unscathed, the company has kept its nutrition business steaming ahead at full speed. The firm reported its most recent quarter's earnings this week, and Abbott's nutrition business has barely slowed down to deal with China's setback.
Nutrition has become Abbott's new growth driver in its post-pharmaceutical life, but should you believe in this blossoming business' future? In the video below, Fool contributor Dan Carroll tells you what you need to know about Abbott's nutritional growth prospects and how this stalwart stock stacks up against the competition.
Fool contributor Dan Carroll has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
This News Explains Why DexCom Is Dropping Today
Shares slide after news breaks that a competitor's product nabs an important reimbursement win.
3 Top Diabetes Stocks to Buy Now
The diabetes market is growing. And these stocks are poised to grow with it.
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
ABT earnings call for the period ending September 30, 2017